Vivani Medical, Inc. (VANI)
NASDAQ: VANI · Real-Time Price · USD
1.050
+0.020 (1.94%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Vivani Medical Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
37
Market Cap
62.21M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
VANI News
- 11 days ago - Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity - GlobeNewsWire
- 26 days ago - Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - Vivani Medical Announces $8.25M Private Placement Equity Financing - GlobeNewsWire
- 4 weeks ago - Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing - GlobeNewsWire
- 4 weeks ago - Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025 - Business Wire
- 6 weeks ago - Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults - Business Wire
- 6 weeks ago - Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business - Business Wire
- 6 weeks ago - EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value - Benzinga